{"organizations": [], "uuid": "864e04bc33df8488fa3907de2f278a1745de4edf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ablynx-fy-operating-loss-widens-to/brief-ablynx-fy-operating-loss-widens-to-54-2-million-euros-idUSFWN1QC05S", "country": "US", "domain_rank": 408, "title": "BRIEF-Ablynx FY Operating Loss Widens To 54.2‍​ Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.214, "site_type": "news", "published": "2018-02-22T14:21:00.000+02:00", "replies_count": 0, "uuid": "864e04bc33df8488fa3907de2f278a1745de4edf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ablynx-fy-operating-loss-widens-to/brief-ablynx-fy-operating-loss-widens-to-54-2-million-euros-idUSFWN1QC05S", "ord_in_thread": 0, "title": "BRIEF-Ablynx FY Operating Loss Widens To 54.2‍​ Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "dec", "sentiment": "none"}, {"name": "caplacizumab", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - ABLYNX NV:\n* FY OPERATING LOSS OF EUR 54.2‍​ MILLION VERSUS LOSS OF EUR 28.6 MILLION YEAR AGO\n* FY NET LOSS OF EUR 108.5‍​ MILLION VERSUS LOSS OF EUR 1.1 MILLION YEAR AGO\n* CASH POSITION AT DEC 31 EUR 354.3‍​ MILLION VERSUS EUR 235.4 MILLION YEAR AGO\n* FY TOTAL REVENUE AND GRANT INCOME EUR ‍​55.5 MILLION VERSUS EUR 85.2 MILLION YEAR AGO\n* MAY RECEIVE MARKETING AUTHORISATION FOR CAPLACIZUMAB IN ATTP IN Q3 2018\n* FOR ALX-0171, A PHASE II STUDY TO BE INITIATED IN H1 2018\n* RESULTS FROM ONGOING ALX-0171 PHASE IIB STUDY IN RSV-INFECTED HOSPITALISED INFANTS ARE EXPECTED IN Q4 2018\n* PHASE II RESULTS FOR VOBARILIZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS EXPECTED IN H1 2018\n* EXPECTS UP TO THREE NANOBODIES TO ENTER PHASE I STUDIES FROM OUR COLLABORATIVE PROGRAMMES DURING 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T14:21:00.000+02:00", "crawled": "2018-02-23T15:39:51.021+02:00", "highlightTitle": ""}